Answers are grounded in this paper and cite their sources.
Measurements of CSF AD biomarkers show large between-laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers.
No takes yet. Share an insight, caveat, or question.
Mattsson et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: